Strategic Alternatives
How to Build and Sell a Biotech in 2024
Jul 8, 2024
CEOs who sold biotechs worth $29bn share insights on M&A. They discuss building strong organizations, understanding value, navigating FTC regulations, analyzing legal principles, and strategic considerations for biotech M&A in 2024.
35:19
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Successful biotech company building involves focusing on operational excellence and team confidence.
- Biopharma M&A success requires understanding buyer perspectives, competitive processes, and revenue generation timelines.
Deep dives
Keys to Successfully Build and Sell a Biotech Company
Building and selling a biotech company involves strategic value creation paths, including standalone development and potential mergers and acquisitions (M&A). CEOs shared insights on focusing on building a great company, having a commercial mindset, and avoiding speculation about M&A to avoid destroying value. They highlighted the importance of operational excellence, developing necessary functions, and building confidence in the management team.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
